[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580305":3},{"organization":4,"armGroups":7,"interventions":57,"overallOfficials":92,"centralContacts":97,"locations":103,"responsibleParty":203,"collaborators":63,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":63,"eligibilityCriteria":211,"healthyVolunteers":207,"sex":212,"minAge":213,"maxAge":63,"enrollmentInfo":214,"targetDuration":63,"studyType":217,"phases":218,"briefSummary":220,"conditions":221,"keywords":227,"overallStatus":106,"whyStopped":63,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},{"fullName":5,"class":6},"Alterome Therapeutics, Inc.","INDUSTRY",[8,14,19,24,29,34,39,43,48,52],{"label":9,"type":10,"description":11,"interventionNames":12},"ALTA3263 monotherapy","EXPERIMENTAL","ALTA3263 will be administered continuously at a protocol-defined dose based on cohort assignment",[13],"Drug: ALTA3263",{"label":15,"type":10,"description":16,"interventionNames":17},"ALTA3263 in combination with cetuximab","ALTA3263 in combination with cetuximab will be administered continuously at a protocol-defined dose based on cohort assignment",[13,18],"Drug: cetuximab",{"label":20,"type":10,"description":21,"interventionNames":22},"ALTA3263 in combination with mFOLFOX6 plus cetuximab","ALTA3263 in combination with modified folinic acid (leucovorin), fluorouracil, and oxaliplatin (mFOLFOX6) and cetuximab will be administered continuously at a protocol-defined dose based on cohort assignment",[13,18,23],"Drug: mFOLFOX6",{"label":25,"type":10,"description":26,"interventionNames":27},"ALTA3263 in combination with pembrolizumab","ALTA3263 in combination with pembrolizumab will be administered continuously at a protocol-defined dose based on cohort assignment",[13,28],"Drug: Pembrolizumab",{"label":30,"type":10,"description":31,"interventionNames":32},"ALTA3263 in combination with pembrolizumab plus chemotherapy","ALTA3263 in combination with pembrolizumab, pemetrexed, and carboplatin\u002Fcisplatin will be administered continuously at a protocol-defined dose based on cohort assignment",[13,28,33],"Drug: Pemetrexed + Cisplatin \u002FCarboplatin",{"label":35,"type":10,"description":36,"interventionNames":37},"ALTA3263 in combination with mFOLFIRINOX","ALTA3263 in combination with modified folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) will be administered continuously at a protocol-defined dose based on cohort assignment",[13,38],"Drug: mFOLFIRINOX",{"label":40,"type":10,"description":41,"interventionNames":42},"ALTA3263 in combination with mFOLFIRINOX plus cetuximab","ALTA3263 in combination with modified folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) plus cetuximab will be administered continuously at a protocol-defined dose based on cohort assignment",[13,18,38],{"label":44,"type":10,"description":45,"interventionNames":46},"ALTA3263 in combination with GnP","ALTA3263 in combination with gemcitabine and albumin-bound paclitaxel will be administered continuously at a protocol-defined dose based on cohort assignment",[13,47],"Drug: GnP",{"label":49,"type":10,"description":50,"interventionNames":51},"ALTA3263 in combination with GnP plus cetuximab","ALTA3263 in combination with gemcitabine, albumin-bound paclitaxel plus cetuximab will be administered continuously at a protocol-defined dose based on cohort assignment",[13,18,47],{"label":53,"type":10,"description":54,"interventionNames":55},"ALTA3263 Midazolam DDI Substudy","ALTA3263 and midazolam will be administered at a protocol defined schedule",[13,56],"Drug: Midazolam",[58,64,68,72,76,80,84,88],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"DRUG","ALTA3263","Oral ALTA3263 tablets will be administered at a protocol-defined dose",[53,44,49,15,35,40,20,25,30,9],null,{"type":59,"name":65,"description":66,"armGroupLabels":67,"otherNames":63},"cetuximab","Cetuximab injection for IV use will be administered at a protocol-defined dose",[49,15,40,20],{"type":59,"name":69,"description":70,"armGroupLabels":71,"otherNames":63},"mFOLFOX6","modified folinic acid (leucovorin), fluorouracil, and oxaliplatin will be administered at a protocol-defined dose",[20],{"type":59,"name":73,"description":74,"armGroupLabels":75,"otherNames":63},"Pembrolizumab","Pembrolizumab injection for IV use will be administered at a protocol-defined dose",[25,30],{"type":59,"name":77,"description":78,"armGroupLabels":79,"otherNames":63},"Pemetrexed + Cisplatin \u002FCarboplatin","Pemetrexed and carboplatin\u002Fcisplatin injection for IV use will be administered at a protocol-defined dose",[30],{"type":59,"name":81,"description":82,"armGroupLabels":83,"otherNames":63},"mFOLFIRINOX","modified folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin will be administered at a protocol-defined dose",[35,40],{"type":59,"name":85,"description":86,"armGroupLabels":87,"otherNames":63},"GnP","gemcitabine and albumin-bound paclitaxel will be administered at a protocol-defined dose",[44,49],{"type":59,"name":89,"description":90,"armGroupLabels":91,"otherNames":63},"Midazolam","Oral midazolam will be administered at a protocol-defined dose",[53],[93],{"name":94,"affiliation":95,"role":96},"Study Medical Director","Alterome Therapeutics","STUDY_DIRECTOR",[98],{"name":99,"role":100,"phone":101,"phoneExt":63,"email":102},"Alterome Clinical Trial Contact Center","CONTACT","619-768-8189","clinical.trials@alterome.com",[104,118,127,132,141,149,154,163,172,181,190,194],{"facility":105,"status":106,"city":107,"state":108,"zip":109,"country":110,"countryCode":111,"cosmosGeoPoint":112,"geoPoint":117,"contacts":63},"Research Site","RECRUITING","Orlando","Florida","32827","United States","US",{"type":113,"coordinates":114},"Point",[115,116],-81.37924,28.53834,{"lat":116,"lon":115},{"facility":105,"status":106,"city":119,"state":120,"zip":121,"country":110,"countryCode":111,"cosmosGeoPoint":122,"geoPoint":126,"contacts":63},"Boston","Massachusetts","02114",{"type":113,"coordinates":123},[124,125],-71.05977,42.35843,{"lat":125,"lon":124},{"facility":105,"status":106,"city":119,"state":120,"zip":128,"country":110,"countryCode":111,"cosmosGeoPoint":129,"geoPoint":131,"contacts":63},"02115",{"type":113,"coordinates":130},[124,125],{"lat":125,"lon":124},{"facility":105,"status":106,"city":133,"state":134,"zip":135,"country":110,"countryCode":111,"cosmosGeoPoint":136,"geoPoint":140,"contacts":63},"St Louis","Missouri","63110",{"type":113,"coordinates":137},[138,139],-90.19789,38.62727,{"lat":139,"lon":138},{"facility":105,"status":106,"city":142,"state":142,"zip":143,"country":110,"countryCode":111,"cosmosGeoPoint":144,"geoPoint":148,"contacts":63},"New York","10016",{"type":113,"coordinates":145},[146,147],-74.00597,40.71427,{"lat":147,"lon":146},{"facility":105,"status":106,"city":142,"state":142,"zip":150,"country":110,"countryCode":111,"cosmosGeoPoint":151,"geoPoint":153,"contacts":63},"10032",{"type":113,"coordinates":152},[146,147],{"lat":147,"lon":146},{"facility":105,"status":106,"city":155,"state":156,"zip":157,"country":110,"countryCode":111,"cosmosGeoPoint":158,"geoPoint":162,"contacts":63},"Durham","North Carolina","27710",{"type":113,"coordinates":159},[160,161],-78.89862,35.99403,{"lat":161,"lon":160},{"facility":105,"status":106,"city":164,"state":165,"zip":166,"country":110,"countryCode":111,"cosmosGeoPoint":167,"geoPoint":171,"contacts":63},"Nashville","Tennessee","37203",{"type":113,"coordinates":168},[169,170],-86.78444,36.16589,{"lat":170,"lon":169},{"facility":105,"status":106,"city":173,"state":174,"zip":175,"country":110,"countryCode":111,"cosmosGeoPoint":176,"geoPoint":180,"contacts":63},"Houston","Texas","77030",{"type":113,"coordinates":177},[178,179],-95.36327,29.76328,{"lat":179,"lon":178},{"facility":182,"status":106,"city":183,"state":174,"zip":184,"country":110,"countryCode":111,"cosmosGeoPoint":185,"geoPoint":189,"contacts":63},"Research Site #2","San Antonio","78229",{"type":113,"coordinates":186},[187,188],-98.49363,29.42412,{"lat":188,"lon":187},{"facility":105,"status":106,"city":183,"state":174,"zip":184,"country":110,"countryCode":111,"cosmosGeoPoint":191,"geoPoint":193,"contacts":63},{"type":113,"coordinates":192},[187,188],{"lat":188,"lon":187},{"facility":105,"status":106,"city":195,"state":196,"zip":197,"country":110,"countryCode":111,"cosmosGeoPoint":198,"geoPoint":202,"contacts":63},"Fairfax","Virginia","22031",{"type":113,"coordinates":199},[200,201],-77.30637,38.84622,{"lat":201,"lon":200},{"type":204,"investigatorFullName":63,"investigatorTitle":63,"investigatorAffiliation":63,"oldNameTitle":63,"oldOrganization":63},"SPONSOR","100580305","phase-1-a-study-to-learn-about-study-medicine-alta3263-in-adults-with-advanced-solid-tumors-with-kras-mutations-100580305",false,"NCT06835569","A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations","A Phase 1\u002F1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.\n* Unresectable or metastatic disease.\n* Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol\n* Known condition that prohibits the ability to swallow or absorb an oral medication.\n\nOther inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":215,"type":216},448,"ESTIMATED","INTERVENTIONAL",[219],"PHASE1","The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.",[222,223,224,225,226],"Cancer","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC (Non-small Cell Lung Cancer)","CRC (Colorectal Cancer)","Advanced Solid Tumors",[228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251],"KRAS mutation","NSCLC","Non-small cell lung cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma","Colorectal carcinoma","Pancreatic cancer","Pancreatic carcinoma","Solid tumors","KRAS","Mutation","Metastatic","Advanced unresectable","Neoplasms","Neoplasms by Site","Carcinoma","Non-small cell lung carcinoma","Non-small cell lung neoplasm","Pancreatic neoplasm","Lung neoplasm","Colorectal neoplasm","Colon neoplasm","Mutant KRAS","KRAS amplification","2026-06-08",{"date":254,"type":255},"2026-06-10","ACTUAL",{"date":257,"type":255},"2025-03-05",{"date":259,"type":216},"2029-08",{"name":5,"class":6},12]